MRKR (Marker Therapeutics) Research & Development: $11.51 Mil (TTM As of Mar. 2026)


MRKR Marker Therapeutics Inc MRKR
32 GF Score
Price $1.32
! 1 Warning Sign
View Full Analysis

What is Marker Therapeutics Research & Development?

Marker Therapeutics MRKR -1.13% 32 Research & Development is $11.51 Mil as of Mar. 2026. GuruFocus rates MRKR with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Marker Therapeutics's Research & Development for the three months ended in Mar. 2026 was $2.84 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $11.51 Mil.

Marker Therapeutics  (NAS:MRKR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Marker Therapeutics Research & Development Related Terms

Marker Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Marker Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marker Therapeutics Research & Development Chart

Marker Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.80 11.97 10.42 13.47 11.80

Marker Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.14 4.18 2.35 2.14 2.84
MRKR
32GF Score
Marker Therapeutics Inc MRKR
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marker Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $11.51 Mil mean?
Marker Therapeutics (MRKR) has a Research & Development of $11.51 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Marker Therapeutics and its competitors.
Is Marker Therapeutics' Research & Development too high?
Marker Therapeutics' current Research & Development is $11.51 Mil. Overall, Marker Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Marker Therapeutics' Research & Development compare to OTLC and ALLR?
Marker Therapeutics' Research & Development of $11.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Marker Therapeutics and its competitors. Marker Therapeutics's current Research & Development is $11.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marker Therapeutics stock overvalued right now?
Marker Therapeutics (MRKR) has a current Research & Development of $11.51 Mil. The current Research & Development is $11.51 Mil. Marker Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Marker Therapeutics (MRKR), the current Research & Development is $11.51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marker Therapeutics Business Description

Other Exchanges GX1:Germany
Address 2450 Holcombe Boulevard, TMC Partners Office 1.311, Houston, TX, USA, 77021
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
32GF Score

Get the complete analysis for MRKR

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32
Price